The degree of complexity and crossover within MAPK signaling, and also shifts in pathways such as nuclear ... and spleen tyrosine kinase (Syk) targets are closer to the cell surface, and seem ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback